SFM
CYTK icon

Sphera Funds Management’s Cytokinetics CYTK Stock Holding History

Sphera Funds Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.62M Sell
39,817
-51,900
-57% -$3.3M 0.42% 72
2025
Q4 		$5.83M Sell
91,717
-69,800
-43% -$4.34M 1.13% 36
2025
Q3 		$8.88M Sell
161,517
-165,201
-51% -$6.81M 1.87% 12
2025
Q2 		$10.8M Buy
326,718
+181,757
+125% +$6.32M 2.53% 6
2025
Q1 		$5.83M Sell
144,961
-8,060
-5% -$370K 1.34% 20
2024
Q4 		$7.2M Sell
153,021
-72,000
-32% -$3.74M 1.3% 23
2024
Q3 		$11.9M Sell
225,021
-159,903
-42% -$8.91M 1.89% 14
2024
Q2 		$20.9M Buy
384,924
+103,253
+37% +$6.23M 2.84% 5
2024
Q1 		$19.7M Buy
281,671
+57,851
+26% +$4.47M 2.77% 6
2023
Q4 		$18.7M Sell
223,820
-10,113
-4% -$366K 3.01% 4
2023
Q3 		$6.89M Buy
+233,933
New +$7.79M 1.26% 23
2020
Q1 		– Sell
-268,747
Closed -$2.85M – 85
2019
Q4 		$2.85M Buy
+268,747
New +$2.76M 0.24% 67
2018
Q1 		– Sell
-210,000
Closed -$1.71M – 120
2017
Q4 		$1.71M Sell
210,000
-17,990
-8% -$204K 0.2% 103
2017
Q3 		$3.31M Buy
227,990
+10,000
+5% +$137K 0.47% 57
2017
Q2 		$2.64M Buy
217,990
+65,790
+43% +$914K 0.45% 70
2017
Q1 		$1.96M Buy
+152,200
New +$1.78M 0.38% 73
2016
Q3 		– Sell
-32,069
Closed -$304K – 113
2016
Q2 		$304K Sell
32,069
-309,875
-91% -$2.54M 0.08% 87
2016
Q1 		$2.41M Buy
+341,944
New +$2.5M 0.52% 38
2015
Q4 		– Sell
-372,250
Closed -$2.49M – 121
2015
Q3 		$2.49M Sell
372,250
-50,000
-12% -$341K 0.32% 77
2015
Q2 		$2.84M Buy
+422,250
New +$2.77M 0.28% 97
2015
Q1 		– Sell
-493,212
Closed -$3.95M – 150
2014
Q4 		$3.95M Buy
493,212
+130,000
+36% +$558K 0.67% 45
2014
Q3 		$1.28M Buy
363,212
+298,112
+458% +$1.25M 0.16% 105
2014
Q2 		$311K Sell
65,100
-64,900
-50% -$396K 0.08% 91
2014
Q1 		$1.24M Sell
130,000
-37,000
-22% -$335K 0.28% 79
2013
Q4 		$1.09M Buy
+167,000
New +$1.1M 0.3% 75

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sphera Funds Management's CYTK Position: Q1 2026 in Review

Sphera Funds Management reduced its Cytokinetics (CYTK) stake by 57% in Q1 2026, selling an estimated $3.3M and leaving 39,817 shares worth $2.62M. The position accounts for 0.42% of the portfolio, ranked #72.

Sphera Funds Management first reported a position in CYTK in Q4 2013 and has held it in 25 quarters since. The position peaked at $20.9M in Q2 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Sphera Funds Management held 39,817 shares of Cytokinetics worth $2.62M as of Q1 2026.
  • Sphera Funds Management sold 51,900 Cytokinetics shares in Q1 2026, an estimated $3.3M.
  • Cytokinetics made up 0.42% of Sphera Funds Management's portfolio in Q1 2026, its #72 holding.
  • Sphera Funds Management first reported a position in Cytokinetics in Q4 2013 and has held it in 25 quarters since.
  • Sphera Funds Management's Cytokinetics position peaked at $20.9M in Q2 2024.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.